Are cost-effectiveness rules in public drug plans denying coverage to Canadians with rare disorders?


Author: Dr. Nigel SB Rawson, Ph.D.

In an analysis of Common Drug Review (CDR) recommendations for 33 drugs published between September 2003 and December 2005, all six drugs for rare disorders received a negative recommendation. A decade later, it is appropriate to review whether any change has occurred in the CDR’s evaluation of drugs for rare disorders. This study evaluates the performance of Canada’s public agencies that conduct Health Technology Assessments (HTA) of new drugs for rare disorders. What are the consequences for patients when HTA methods are too rigid?